Astellas Lifts Profit Forecast on Lower R&D Costs, Land Sale

Astellas Pharma Inc., Japan’s third-largest drugmaker, increased its full-year profit forecast by 4.9 percent because of lower research and development costs and a gain from the sale of land.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.